Haleon (HLN) Other Accumulated Expenses (2021 - 2022)

Haleon (HLN) posted Other Accumulated Expenses of -$39.0 million for Q2 2022, down 7.26% on a QoQ basis from -$36.4 million in Q4 2021.

Haleon (HLN) Other Accumulated Expenses (2021 - 2022) Analysis & Trends

Haleon's Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at -$39.0 million for Q2 2022.

  • Quarterly Other Accumulated Expenses changed N/A year-over-year to -$39.0 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was -$39.0 million (changed N/A YoY) and the FY2021 annual result came in at -$37.1 million, changed N/A from the prior year.
  • Other Accumulated Expenses was -$39.0 million for Q2 2022 at Haleon, down from -$36.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at -$36.4 million in Q4 2021 and bottomed at -$39.0 million in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn

Historic Data

Download Data
DateValue
Jun 30, 2022 -39.04 Mn
Dec 31, 2021 -36.40 Mn